Phase I Trial Evaluating the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Dasatinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.